Corrigendum to “mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)”
Ralf‐Dieter Hofheinz, F. Herrle, Tobias Dechow, Ludwig Fischer von Weikersthal et autres